First case series on the use of imiquimod for morphoea.
作者信息
Dytoc M, Ting P T, Man J, Sawyer D, Fiorillo L
机构信息
Faculty of Medicine, University of Calgary, Calgary, Alberta T6G 2G3, Canada.
出版信息
Br J Dermatol. 2005 Oct;153(4):815-20. doi: 10.1111/j.1365-2133.2005.06776.x.
BACKGROUND
Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)-beta.
OBJECTIVE
Our objective was to use imiquimod 5% cream (Aldara), an inducer of interferon-gamma, known to inhibit TGF-beta, to treat morphoea.
METHODS
Patients with morphoea were treated with imiquimod and evaluated during their follow-up visits to 6 months.
RESULTS
The dyspigmentation, induration and erythema of 12 patients with morphoea lesions improved. The histology of the skin also showed a decrease in dermal thickness.
CONCLUSION
This is the first case series describing the successful application of imiquimod in the management of morphoea.
Zotero 插件